Stocks · News reference
Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway
Scinai Immunotherapeutics CEO Amir Reichman issued a shareholder letter detailing growth in the company's CDMO business and an extended operating runway following recent financing.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Scinai Immunotherapeutics shares are trading lower after the company announced a $4 million private placement and warrant inducement transaction.
Scinai Immunotherapeutics Announces ~$4M Financing Via $1.20/ADS Private Placement And Warrant Inducement Repricing April 2026 Warrants To $1.20/ADS
Why Is Scinai Immunotherapeutics Stock Gaining Tuesday?
Scinai Immunotherapeutics stock jumped 27% after securing a $5.1M biopharma manufacturing deal. Details on SCNI's major contract win.
Scinai Immunotherapeutics shares are trading higher after the company announced a development and manufacturing agreement with a biopharma company, boosting committed customer orders to $7.6 million, up 300% from year-end 2025.
Scinai Expands CDMO Business with $5.1M Development and Clinical Manufacturing Agreement